Heart failure – can be treated by affecting cardiac metabolism?

Česká verzia

Authors: Ján Murín; Miroslav Pernický; Soňa Kiňová
Authors place of work: I. interná klinika LF UK a UN Bratislava, Slovenská republika, prednostka doc. MUDr. Soňa Kiňová, CSc.
Published in the journal: Vnitř Lék 2014; 60(5-6): 437-441
Category: Review

Summary

Chronic heart failure is a disease of epidemic extent and has a high mortality and morbidity. Etiology is multifactorial, but the issue is that heart does not have “enough fuel” to produce energy for its work or available fuel can´t be properly utilized. Components of cardiac energy metabolism are substrate utilization, oxidative phosphorylation and ATP (adenosine triphosphate) transfer and utilization. The aim of article is to present the function of heart metabolism and how “metabolic dysfunction” contributes to heart failure. Perhaps, drug effect on heart metabolism is an approach to treatment of chronic heart failure.

Key words:
cardiac energy metabolism – energy metabolism regulators – heart failure – treatment of heart failure

Zdroje

1. Ingivall JS, Weiss RG. Is the failing heart energy starved ? On using chemical energy to support cardiac function. Circ Res 2004; 95(2): 135–145.

2. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004; 110(8): 894–896.

3. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004; 555(Pt 1): 1–13.

4. Morrov DA, Givertz MM. Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation 2005;112(21):3218–3221.

5. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J. 2004; 25(20):1765–1768.

6. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316(23): 1429–1435.

7. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction — Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677.

8. A randomized trial of β-blockade in heart failure: the Cardiac Bisoprolol Insufficiency study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90(4): 1765–1773.

9. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349–1355.

10. Cohn JN, Tognoni G (Valsartan Heart Failure Trial Investigators). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667–1675.

11. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–766.

12. Špinar J, Vítovec J. Metabolický syndrom a kardiovaskulární onemocnení. Vnitř Lék 2009; 55(7–8): 653–658.

13. Špác J, Beránek M, Němcová H et al. Využití natriuretických peptidu v diagnostice hypertrofie levé komory srdeční u obézních hypertoniku s metabolickým syndromem. Vnitř Lék 2013; 59(9): 769–775.

14. Kvapil M. Diabetické srdce či srdce diabetika? Vnitř Lék 2005; 51(3): 270–271.

15. Bessman SP, Geiger PJ. Transport of energy in muscle: the phosphorylcreatine shuttle. Science 1981; 211 (4481): 448–452.

16. Wallimann T, Wyss M, Brdiczka D et al. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the “phosphocreatine circuit” for cellular energy homeostasis. Biochem J 1992; 281(Pt 1): 21–40.

17. Guimbal C, Kilimann MWA. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney: cDNA cloning and functional expression. J Biol Chem 1993; 258(12): 8418–8421.

18. Ingwall JS. ATP and the heart. Kluwer Academic Publishers: Norwell, MA, 2002. ISBN 1–4020–7093–4.

19. Igwall JS. Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 1982; 242(5): H729-H744.

20. Neubauer S, Horn M, Cramer M et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96(7): 2190–2196.

21. Wallhaus TR, Taylor M, DeGrado TR et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271–277.

22. Davila-Roman VG, Vedala G, Herrero P et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40(2): 271–277.

23. Ning XH, Zhang J, Liu J et al. Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction. J Am Coll Cardiol 2000; 36(1): 282–287.

24. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85(3): 1093–1129.

25. Chandler MP, Kerner J, Huang H et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004; 287(4): H1538-H1543.

26. Osorio JC, Stanley WC, Linke A et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002; 106(5): 606–612.

27. Taylor M, Wallhaus TR, Degrado TR et al. An evaluation of myocardial fatty acid and glucose uptake using PET with (18F)fluoro-6-thia-heptadecanoic acid and (18)FDG in patients with congestive heart failure. J Nucl Med 2001; 42(1): 55–62.

28. Marín-Garcia J, Goldenthal MJ, Moe GW. Abnormal cardiac and skeletal muscle mitochondrial function in pacing-induced cardiac failure. Cardiovasc Res 2001; 52(1): 103–110.

29. Quigley AF, Kapsa RM, Esmore D et al. Mitochondrial respiratory chain activity in idiopathic dilated cardiomyopathy. J Card Fail 2000; 6(1): 47–55.

30. Casedemont J, Miro O Electron transport chain defects in heart failure. Heart Fail Rev 2002; 7(2): 131–139.

31. Murray AJ, Anderson RE, Watson GC et al. Uncoupling proteins in human heart. Lancet 2004; 364 (9447): 1786–1788.

32. Starling RC, Hammer DF, Altschuld RA Human myocardial ATP content and in vivo contractile function. Mol Cell Biochem 1998;180(1–2): 171–177.

33. Beer M, Seyfarth T, Sandstede J et al. Absolute concentrations of high-energy phosphae metabolities in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLLOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002; 40(7): 1267–1274.

34. Ten Hove M, Chan S, Lygate C et al. Mechanisms of creatine depletion in chronically failing rat heart. J Mol Cell Cardiol 2005;38(2):309–313.

35. Neubauer S, Remkes H, Spindler M et al. Downregulation of the Na(+)-creatine cotransporter in failing human myocadium and in experimental heart failure. Circulation 1999; 100(18): 1847–1850.

36. Neubauer S, Hor M, Naumann A et al. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 1995; 95(3): 1092–1110.

37. Weiss RG, Gerstenblith G, Bottomley PA. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci USA 2005; 102(3): 808–813.

38. Liao R, Nascimben L, Frriedrich J et al. Decreased energy reserve in an animal model of dilated cardiomyopathy: relationship to contractile performance. Circ Res 1996; 78(5): 893–902.

39. Liu J, Wang C, Murakami Y et al. Mitochondrial ATPase and high-energy phospates in failing hearts. Am J Physiol Heart Circ Physiol 2001; 281(3): H1319-H1326.

40. Hardy CJ, Weiss RG, Bottomley PA et al. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 122(3 Pt 1): 795–801.

41. Neubauer S, Krahe T, Schindler R et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992; 86(6): 1810–1818.

42. Conway MA, Allis J, Ouwerkerk R et al. Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991; 338 (8773): 973–976.

43. Neubauer S, Hor M, Pabst T et al. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995; 16: (Suppl. O):115–118.

44. Lamb HJ, Beyerbacht HP, van der Laarse A et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99(17): 2261–2267.

45. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 2004; 95(6): 568–578.

46. Karbowska J, Kochan Z, Smolenski RT. Perixisome proliferator-activated receptor alpha is downregulated in the failing human heart. Cell Mol Biol Lett 2003; 8(1): 49–53.

47. Arany Z, Novikov M, Chin S et al. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1 alpha. Proc Natl Acad Sci USA 2006; 103(26): 10086–10091.

48. Exil VJ, Roberts RL, Sims H et al. Very-long-chain acyl-coenzyme. A dehydrogenase deficiency in mice. Circ Res 2003; 93(5): 448–455.

49. Luptak I, Balschi JA, Xing Y et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts cna be rescued by increasing glucose transport and utilization. Circulation 2005; 112(15): 2339–2346.

50. Russel LK, Finck BN, Kelly DP. Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol 2005; 38(1): 81–91.

51. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol 2000; 81(6): 349–372.

52. Herrmann HP, Pieske B, Schwarzmuller E et al. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999; 353 (9161): 1321–1323.

53. Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110(8): 955–961.

54. Liao R, Jain M, Cui L et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 2002; 106(16): 2125–2135.

55. Visale C, Wajngaten M, Sposato B et al. Trimetrazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25(20): 1814–1821.

56. Di Napoli P, Taccardi AA, Barsotti. A Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005; 91(2): 161–165.

57. Lee L, Campell R, Scheuermann-Freestone M et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112(21): 3280–3288.

58. Smidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000; 99(1): 27–35.

59. Wallis J, Lygate CA, Fischer A et al. Supranormal myocardial creatine and phosphocreatine concentrations lead to cardiac hypertrophy and heart failure insights from creatine transporter-overexpressing transgenic mice. Circulation 2005; 112(20): 3131–3139.

60. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy 2004; 24(10): 1366–1384.